ArticleJournal of hepatocellular carcinoma2025
Prognostic Signature of NETs-Related Genes in Hepatocellular Carcinoma Based on Bulk and Single-Cell Transcriptomics.
Article in Journal of hepatocellular carcinoma, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The Molecular Network of Neutrophil Extracellular Traps in Hepatocellular Carcinoma: Biogenesis, Function, and Therapeutic Implications.Molecules (Basel, Switzerland) · 2026Review
- The Role of Neutrophil Extracellular Traps in Hepatocellular Carcinoma. What Are the Implications of Anesthetic Techniques? A Narrative Review.International journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Inflammation drives tumor development, with neutrophil extracellular traps (NETs) promoting progression through metastasis, immune suppression, and microenvironment modulation. However, the role of NETs-related genes in hepatocellular carcinoma (HCC) immunity response is still unclear. Methods: We integrated single-cell RNA sequencing (GSE202642, seven tumor samples and four normal liver samples) and The Cancer Genome Atlas (TCGA, n=312) transcriptomic data to identify NETs-related gene signatures. Weighted gene co-expression network analysis (WGCNA) identified NETs-correlated gene modules, and LASSO-COX regression selected prognostic genes for risk stratification. A nomogram was developed to predict survival, while functional, mutation, immune, and drug sensitivity analyses highlighted intergroup differences. EdU and CCK-8 cell proliferation assays confirmed the role of NETs-related genes in HCC cell proliferation. Results: The analysis revealed significant differences in survival time between high- and low-NETs groups. GAS2L3 and RTN3 were identified and validated as independent prognostic factors. ROC and decision curve analysis (DCA) demonstrated that the nomogram model combining NETs risk scores with clinical parameters exhibited robust prognostic performance. The high-risk subgroup was enriched in glycosphingolipid biosynthesis pathways and showed higher mutati843on rates, especially in TP53, CTNNB1, and MUC16, along with overexpression of immunosuppressive genes (VTCN1, LAIR1). In vitro experiments confirmed that GAS2L3 knockdown inhibited HepG2 and Huh7 cell proliferation. Conclusion: Integrated multi-omics analysis revealed NETs-associated prognostic signatures in HCC, with GAS2L3 identified as a key gene linking NETs to tumor progression and therapeutic potential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.